Navigation Links
Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)
Date:1/11/2011

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)

http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html

Drug delivery is evolving at a rapid rate with new drug product formulations being discovered frequently. Advanced drug delivery deals with developing solutions for new entities in therapeutic pharmacology such as protein and peptides and other novel compounds targeting drugs to specific disease sites including gene therapy. Treatments for chronic conditions and growth in patient-administered drugs are factors leading to greater focus on ease-of-use and convenience.

Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) details the types of drug delivery systems, technologies and products utilizing advanced drug delivery systems The report describes the industry, its relationship to various healthcare channels, and the trends for the future.

The advanced drug delivery market is two-fold. First of all it identifies drug delivery technology Secondly, it identifies products in the pharmaceutical arena that utilize those drug delivery technologies. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales. This report will provide market data that includes the pharmaceutical revenues of those products that utilize advanced drug delivery.

In this report, the advanced drug delivery market is divided into three main segments and market estimates are provided for indications within each category:

  • Liposome Drug Delivery (by Indication - Fungal Infections Cancer, Others)

  • Polymer Drug Delivery (by Indication - Cancer, Neutropenia, Hepatitis, Contraception, Schizophrenia, Acromegaly and Others)

  • Monoclonal Antibodies Drug Delivery (by Indication - Arthritis, Cancer, Multiple Sclerosis, Macular Degeneration, Respiratory Syncytial Virus, Others)

  • The following types of polymer delivery drugs are segmented within this report.

  • PEGylated Delivery

  • Emulsion Delivery

  • Injectable Delivery

  • Nanoparticle Delivery

  • Others

  • A wide range of trends and issues that will impact the advance drug delivery market are discussed in the report including the current state of biotechnology expansion, molecular imprinted polymers, hot-melt extrusion, metallofullerenes, nanotechnology advancements and other emerging Drug Delivery technologies not yet on the market.

    The following companies are profiled in the report:

  • Alkermes, Inc.

  • ALZA Corporation

  • AP Pharma

  • Centocor Ortho Biotech, Inc.

  • Eisai , Inc

  • Elan Corporation, Plc

  • EnColl Corporation, Inc.

  • Enzon Pharmaceuticals, Inc

  • Gilead Sciences, Inc.

  • Nektar Therapeutics

  • PDL BioPharma

  • pSivida Corp

  • SurModics, Inc

  • Tolmar, Inc

  • The research conducted by Kalorama Information included comprehensive research of primary and secondary sources such as interviews with company executives, company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and data-based searches, as well as via interviews with key personnel. Person-to-person and telephone interviews were the primary method of gathering information. E-mail correspondence was also used in the interview process. Interviews with 24 key industry officials, trade association spokespersons, consultants, healthcare providers, and government personnel were compiled to form the primary basis of information - particularly revenue and market share data- presented in this report.

    All market data pertains to the worldwide market at the manufacturers' level and was measured in U.S. dollars. The base year for data was 2010. Historical data are provided for 2006 through 2009, with forecast data provided for 2010 through 2014. Compound annual growth rates (CAGR) are provided for the 2006-2010, 2010-2014 and 2006-2014.

    To order this report:: Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.com US: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    2. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
    3. Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth
    4. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
    5. Reportlinker Adds Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile
    6. Reportlinker Adds Cosmetic Surgery Products
    7. Reportlinker Adds Regenerative Medicine Markets
    8. Reportlinker Adds Womens Health Diagnostic Testing
    9. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
    10. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
    11. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
    (Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
    (Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
    (Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
    (Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
    (Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
    Breaking Medicine News(10 mins):